Crystal Brown
Obstetrics & Gynecology · Mount Vernon, KYNPI 1063494045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by AbbVie at 26.6% of the total. Reporting peaked in 2022 at $1,436 and has fallen 59.1% since, to $588 in 2025. Among obstetrics & gynecology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$689
- Novo Nordisk$533
- Lilly USA, LLC$346
- Pfizer$339
- Bayer$191
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,066 in reported general payments places this provider in the 90th percentile of 474 obstetrics & gynecology providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 19 | $30,339 |
| MounjaroTirzepatide | 20 | $28,759 |
| OzempicSemaglutide | 22 | $28,093 |
| MyrbetriqMirabegron | 15 | $14,642 |
| KerendiaFinerenone | 14 | $13,448 |
| Repatha SureclickEvolocumab | 21 | $13,208 |
| LinzessLinaclotide | 14 | $11,556 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,692 |
| Estradiol | 69 | $2,317 |
| ValacyclovirValacyclovir Hcl | 18 | $1,094 |
| Celecoxib | 24 | $796 |
| Levothyroxine Sodium | 116 | $774 |
| Duloxetine Hcl | 19 | $521 |
| Rosuvastatin Calcium | 73 | $453 |
| Pravastatin Sodium | 51 | $428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $102 | $30,33919 claims |
| Lilly USA, LLCMounjaro | $346 | $28,75920 claims |
| Novo NordiskOzempic | $533 | $28,09322 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $14,64215 claims |
| BayerKerendia | $191 | $13,44814 claims |
| AbbVieLinzess | $1,348 | $11,55614 claims |
| AstraZenecaSymbicort | $53 | $4,69213 claims |
| Almatica Pharma LLCSertraline Hcl | $25 | $15617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 obstetrics & gynecology providers in Kentucky.
Other obstetrics & gynecology in Mount Vernon
- Nathan SticeBowling Green$199K
- John BrunerSomerset$82K
- Resad PasicLouisville$39K
- Wendy JacksonLexington$37K
- Bradley YoukilisLouisville$29K
- Travis GilbertCorbin$28K
- James GuilerLexington$25K
- Gigi GirardLouisville$23K
- Jonathan AbbottHopkinsville$18K
- Matthew PriceMurray$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.